Benzinga | Dec 14, 2021 04:10PM EST

Aurora Cannabis, 22nd Century Reports 3-Way Non-Exclusive License Deal For Biosynthesis Intellectual Property To Cronos Group, 'intended to assist in the advancement of research and development on the biosynthesis of cannabinoids,' No Terms Disclosed

Licensing deal set to assist in the advancement of research and development for cannabinoid biosynthesis

EDMONTON, AB, Dec. 14, 2021 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) ("Aurora"), the Canadian company defining the future of cannabinoids worldwide, together with 22nd Century Group, Inc. (NASDAQ:XXII) ("22nd Century") announced today a three-way non-exclusive agreement to license biosynthesis intellectual property to Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos Group"), intended to assist in the advancement of research and development on the biosynthesis of cannabinoids.



Biosynthesis, a process common in the pharmaceutical industry, involves using living micro-organisms to convert simple substances into complex compounds. Through biosynthesis, cannabinoids, particularly those that are rare such as cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), are expected to be produced efficiently and reliably at high levels of purity.

"We are deeply interested in the evolution of cannabinoids, and this is a promising step toward the commercialization of cannabinoid products using biosynthesis," says Miguel Martin, Chief Executive Officer of Aurora. "The long-term potential for rare cannabinoid molecules produced through biosynthesis is incredibly promising given their efficient production methods, and potential therapeutic benefits and utility in health, wellness, and consumer products."

Aurora's connection to the biosynthetic production of cannabinoids originated with early work carried out by the Company's former Chief Science Officer on the discovery of key genes within the cannabinoid biosynthesis pathway.

"This license combines the resources and intellectual property of all three companies in this agreement intended to facilitate the commercial success of a biosynthetic approach, which complements the disruptive plant-based advancements 22nd Century and Aurora continue to develop to bring more consistent and higher yields to the hemp and cannabis industry," said James A. Mish, Chief Executive Officer of 22nd Century Group. "We believe that the availability of both plant-based and biosynthetic cannabinoids will be important to the commercial success of our industry, and this agreement positions 22nd Century, Aurora and Cronos Group with an important role in each approach."

"Cronos Group has successfully commercialized the first cultured cannabinoid product in Canada. Licensing this intellectual property provides us with a component of the process that could allow for increased speed and efficiency in the development and commercialization of cultured cannabinoids," said Kurt Schmidt, President and Chief Executive Officer, Cronos Group.

Through licensing agreements, Aurora and 22nd Century Group together share the global IP rights to commercialize key aspects of cannabinoid biosynthesis in plants and micro-organisms. The two companies are working closely to enforce their IP against infringing parties, as well as to actively explore commercial development opportunities.